Necrotising soft tissue infections
Tidsskr Nor Laegeforen. 2024 Feb 26;144(3).
doi: 10.4045/tidsskr.23.0720.
Print 2024 Feb 27.
[Article in
English,
Norwegian]
Authors
Ingunn Margareetta Gundersen
1
, Trond Bruun
1
, Stian Kreken Almeland
2
, Dag Harald Skutlaberg
3
, Torbjørn Nedrebø
4
, Eivind Rath
5
, Oddvar Oppegaard
1
, Anne Berit Guttormsen
6
, Anna Norrby-Teglund
7
, Knut Anders Mosevoll
1
, Steinar Skrede
1
Affiliations
- 1 Seksjon for infeksjonssjukdommar, Medisinsk klinikk, Haukeland universitetssjukehus, og, Klinisk institutt 2, Det medisinske fakultet, Universitetet i Bergen.
- 2 Avdeling for plastikk-, hand- og rekonstruktiv kirurgi, og, Brannskadeavdelinga, Haukeland universitetssjukehus, og, Klinisk institutt 1, Det medisinske fakultet, Universitetet i Bergen.
- 3 Mikrobiologisk avdeling, Haukeland universitetssjukehus.
- 4 Seksjon for hyperbarmedisin, Yrkesmedisinsk avdeling, og, Kirurgisk serviceklinikk, Haukeland universitetssjukehus.
- 5 Seksjon for infeksjonssjukdommar, Medisinsk klinikk, og, Mottaksklinikken, Haukeland universitetssjukehus.
- 6 Klinisk institutt 1, Det medisinske fakultet, Universitetet i Bergen, og, Kirurgisk serviceklinikk, Haukeland universitetssjukehus.
- 7 Center for infektionsmedicin, Karolinska Institutet, Karolinska Universitetssjukhuset.
Abstract
Necrotising soft tissue infections can affect the skin, subcutaneous tissue, superficial fascia, deep fascia and musculature. The infections are severe, they spread quickly and can result in extensive tissue loss. Although rare, morbidity and mortality rates are high. Early clinical identification is crucial for the outcome, and rapid infection control through surgery and targeted antibiotic treatment is needed to save lives. Few prospective clinical trials have been conducted for the treatment of this type of infection. Specific challenges include rapid identification of the condition and the uncertain efficacy of the various treatment options. In this clinical review article, we describe clinical characteristics, diagnostics and treatment.
MeSH terms
-
Anti-Bacterial Agents / therapeutic use
-
Debridement
-
Fasciitis, Necrotizing* / diagnosis
-
Fasciitis, Necrotizing* / drug therapy
-
Humans
-
Prospective Studies
-
Soft Tissue Infections* / diagnosis
-
Soft Tissue Infections* / drug therapy